Chemerin and apelin are positively correlated with inflammation in obese type 2 diabetic patients

What Was Tested

This randomized controlled trial paper looks at Apelin.

The aim of this study was to investigate whether chemerin and apelin play an important role in the pathophysiologic proceeding of diabetes.

Who Took Part

The study group was 2 patients.

This study enrolled 81 newly diagnosed obese type 2 diabetes mellitus (T2DM) patients (T2DM group, n = 81).

All the patients were randomly assigned to DM1 group treated with metformin (n = 41) and DM2 group treated with pioglitazone (n = 40).

How the Study Was Run

The researchers set it up as a randomized study.

The patients were allocated by chance, so the Apelin group and the comparison group should start out alike.

After hypoglycemic agents treatment, patients under better blood glucose control were chosen to be given antioxidant treatment.

Another 79 subjects without T2DM were recruited as normal control group (NC group), including 40 subjects (NC1 group) with normal body mass index (BMI) and 39 obese subjects (NC2 group).

Levels of chemerin, apelin, BMI, tumor necrosis factor-α (TNF-α), homeostasis model assessment of IR (HOMA-IR) and 8-isoprotaglandim F2α (8-iso-PGF2α) were examined at baseline and post-treatment.

The relationship between chemerin, apelin and BMI, TNF-α, HOMA-IR, 8-iso-PGF2α was analyzed.

What Was Measured

The subject headings attached to it are Apelin, Blood Glucose, Body Mass Index, Chemokines, Diabetes Mellitus, Type 2, Dinoprost and Hypoglycemic Agents.

What This Means in Plain Language

The paper is a randomized study of Apelin in 2 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 11 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2012 (Chinese medical journal), a journal based in China.

More context: the Apelin compound page, all human trials.